Regarding the LSC identification, in 2014 Hermann and colleagues identified the enzyme dipeptidyl-peptidase-IV (DPPIV/CD26) as a specific marker of the CD34+/CD38- leukemic progenitors, demonstrating in a murine model that these cells were able to summarize the CML onset and that they decreased remarkably during the successful treatment with imatinib (13). Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.